Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025)

AVITA Medical (RCEL) has disclosed Cash from Financing Activities for 5 consecutive years, with $248000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 75.71% year-over-year to $248000.0, compared with a TTM value of $14.9 million through Dec 2025, up 325.77%, and an annual FY2025 reading of $14.9 million, up 325.77% over the prior year.
  • Cash from Financing Activities was $248000.0 for Q4 2025 at AVITA Medical, down from $13.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $39.4 million in Q4 2023 and bottomed at $1000.0 in Q1 2022.
  • Average Cash from Financing Activities over 4 years is $4.3 million, with a median of $615500.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities skyrocketed 17000.0% in 2023, then crashed 97.41% in 2024.
  • Year by year, Cash from Financing Activities stood at $899000.0 in 2022, then soared by 4286.21% to $39.4 million in 2023, then plummeted by 97.41% to $1.0 million in 2024, then plummeted by 75.71% to $248000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for RCEL at $248000.0 in Q4 2025, $13.8 million in Q3 2025, and $559000.0 in Q2 2025.